Information Provided By:
Fly News Breaks for November 2, 2015
CTIC
Nov 2, 2015 | 06:49 EDT
Piper Jaffray analyst Charles Duncan views CTI BioPharma's 50,000 preferred stock issuance as a positive. The company now has adequate cash into 2017 absent milestone payment inflows, Duncan tells investors in a research note. The analyst sees 2016 as "transformational" for CTI and reiterates an Overweight rating on the name with an $8 price target.
News For CTIC From the Last 2 Days
There are no results for your query CTIC